RNA-seq analysis of paclitaxel-resistant gastric cancer cells (SNU16/PR) and response to utidelone (UTD1) treatment
This study aims to investigate the transcriptional reprogramming underlying acquired paclitaxel (PTX) resistance in gastric cancer and to elucidate the molecular mechanisms by which the novel epothilone analog utidelone (UTD1) overcomes this resistance. We performed genome-wide RNA sequencing (RNA-seq) on three groups of gastric cancer cells (n = 3 biological replicates per group): parental PTX-sensitive SNU16 cells, acquired PTX-resistant SNU16/PR cells, and SNU16/PR cells treated with UTD1. The data will be used to identify differentially expressed genes (DEGs) and key signaling pathways associated with chemoresistance and drug sensitivity, providing insights into potential therapeutic targets for overcoming taxane resistance in solid tumors.